Publicação

Molecular imaging agents for detection of β-amyloid plaques in Alzheimer’s disease

Ver documento

Detalhes bibliográficos
Resumo:The formation of amyloid structures is a neuropathological feature that characterizes several neurodegenerative disorders, such as Alzheimer´s and Parkinson´s disease. Up to now, the definitive diagnostic of these diseases can only be accomplished by immunostaining of post-mortem brain tissues with dyes such as Thioflavin T and congo red. Aiming at early in vivo diagnosis of Alzheimer´s disease (AD), several amyloid-avid radioprobes have been developed for β-amyloid imaging by positron emission tomography (PET) and single-photon emitted computed tomography (SPECT). The aim of this paper is to present a perspective of the available amyloid imaging agents, special those that have been selected for clinical trials and are at the different stages of US Food and Drugs Administration (FDA) approval.
Autores principais:Quental, Letícia
Outros Autores:Ribeiro Morais, Goreti; Santos, Isabel; Paulo, António
Assunto:Doença de Alzheimer Agregação da β-amilóide Imagiologia molecular Sondas moleculares Alzheimer's disease β-Amyloid aggregation Molecular imaging Molecular probes
Ano:2013
País:Portugal
Tipo de documento:artigo
Tipo de acesso:unknown
Instituição associada:Instituto Politécnico de Lisboa Escola Superior de Tecnologia da Saúde de Lisboa
Idioma:inglês
Origem:Saúde & Tecnologia

Registos relacionados

Registos relacionados